CRISPR Cure for Sickle Cell Disease and Gene Therapy for Blindness Win 2026 Breakthrough Prizes

Two separate teams of scientists whose work transformed theoretical gene editing into actual medical cures for inherited blood disorders and blindness received Breakthrough Prize recognition on April 18, in what prize organizers called an acknowledgment that the CRISPR revolution has moved decisively from laboratory demonstration to patient bedside.

Stuart H. Orkin of Harvard Medical School and Dana-Farber Cancer Institute and Swee Lay Thein of the National Heart, Lung, and Blood Institute were awarded the $3 million Breakthrough Prize in Life Sciences for the foundational molecular biology work that made Casgevy possible — the first CRISPR-based medicine approved for any disease anywhere in the world. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, received U.S. Food and Drug Administration approval in December 2023 to treat sickle cell disease and beta-thalassemia, two inherited blood disorders that affect hundreds of thousands of people globally and disproportionately affect populations of African and Mediterranean ancestry.

Orkin and Thein spent decades investigating why some individuals with sickle cell disease experience milder symptoms than others, eventually identifying that high levels of fetal hemoglobin — a form of the oxygen-carrying protein that functions even when the disease-causing adult form is defective — provide natural protection. Their discovery of the genetic switches that silence fetal hemoglobin production after birth gave the CRISPR community a clear and validated therapeutic target: if those switches could be permanently turned off, the patient's own body would produce the fetal hemoglobin needed to compensate for the defective adult version.

A second Life Sciences prize went to Jean Bennett and Albert Maguire of the University of Pennsylvania and Katherine A. High of Spark Therapeutics for developing Luxturna — the first FDA-approved gene replacement therapy. Luxturna restores functional vision in children and adults with Leber congenital amaurosis caused by mutations in the RPE65 gene, a previously untreatable form of inherited blindness that causes progressive vision loss beginning in childhood. Clinical trials showed that a single injection of the therapy could measurably improve light sensitivity, visual field, and the ability to navigate independently in low-light conditions in patients who had previously been functionally blind.

A third Life Sciences award went to Rosa Rademakers of the Mayo Clinic and Bryan Traynor of the National Institute on Aging for discovering that an expansion in the C9orf72 gene is the most common genetic cause of both ALS — the degenerative motor neuron disease also known as Lou Gehrig's disease — and frontotemporal dementia. The mutation accounts for approximately one-third of familial ALS cases in European populations and had remained unidentified until the two researchers independently found it in 2011, immediately redirecting global ALS research toward new therapeutic targets.

The 2026 Breakthrough Prizes, co-funded by Mark Zuckerberg and Priscilla Chan along with Sergey Brin, Yuri Milner, and Anne Wojcicki, awarded $18.75 million in total prizes across fundamental physics, life sciences, and mathematics — the fifteenth year of a prize that has become one of the most prestigious in science. Prize organizers noted that the 2026 cohort represents an unusual concentration of awards for work that has directly resulted in approved treatments reaching patients.